FREMONT, Calif.--(BUSINESS WIRE)--Ultima Genomics, a developer of an innovative new ultra-high throughput sequencing architecture, today announced that Mark Stevenson will join its Board of Directors. Mark brings more than 30 years of experience and leadership in the Life Sciences sector, most recently serving as Executive Vice President and Chief Operating Officer at Thermo Fisher Scientific, where he was responsible for the portfolio of life science, analytical and diagnostic businesses as well as the innovation and digital strategy..

加利福尼亚州弗里蒙特（商业新闻短讯）--创新新型超高通量测序体系结构的开发人员Ultima Genomics今天宣布，马克·史蒂文森将加入其董事会。Mark在生命科学领域拥有30多年的经验和领导才能，最近担任Thermo Fisher Scientific的执行副总裁兼首席运营官，负责生命科学、分析和诊断业务以及创新和数字战略。。

“Mark brings a wealth of valuable experience having led the innovation and commercial launch of a range of next-generation sequencing technologies now broadly used across both the life sciences research and clinical markets,” said Gilad Almogy, CEO and founder of Ultima Genomics. “Mark is an accomplished leader in life sciences and a tenured executive, advisor and board member for large and global organizations.

Ultima Genomics首席执行官兼创始人吉拉德·阿尔莫基（GiladAlmogy）表示：“马克带来了丰富的宝贵经验，领导了一系列下一代测序技术的创新和商业启动，这些技术现已广泛应用于生命科学研究和临床市场。”。“马克是生命科学领域的杰出领导者，是大型和全球性组织的终身高管、顾问和董事会成员。

His background and leadership experience will be a tremendous asset as we build upon the successful launch of our first system using our new sequencing architecture.”.

随着我们使用新的测序架构成功启动第一个系统，他的背景和领导经验将成为一笔巨大的财富。”。

“Ultima has demonstrated a commitment to challenging the conventional approach, shown through its progress in maturing such a differentiated technology,” said Mark Stevenson. “We are still in the early days of genomics’ impact on healthcare, and technological advancements like Ultima’s sequencing technology will enable more research and better clinical tests to advance the life sciences field.

马克·史蒂文森（MarkStevenson）表示：“Ultima已经证明了它对挑战传统方法的承诺，这体现在它在成熟这种差异化技术方面取得的进展。”。“我们仍处于基因组学对医疗保健影响的早期阶段，像Ultima测序技术这样的技术进步将使更多的研究和更好的临床测试能够推进生命科学领域。

I believe this technology has the potential to open entirely new opportunities to deploy genomics at scale.”.

我相信这项技术有可能为大规模部署基因组学开辟全新的机会。”。

Mark continues to serve on the Scientific Advisory Board of Thermo Fisher Scientific. He is also on the boards of Ingersoll Rand Inc. (NYSE: IR), and Harbinger Health and is a senior advisor at General Atlantic.

Mark继续担任Thermo Fisher Scientific的科学顾问委员会成员。他还是英格索兰公司（NYSE:IR）和先兆健康公司（Harbinger Health）的董事会成员，也是通用大西洋公司（General Atlantic）的高级顾问。

About Ultima Genomics

关于Ultima Genomics

Ultima Genomics is unleashing the power of genomics at scale. The Company's mission is to continuously drive the scale of genomic information to enable unprecedented advances in biology and improvements in human health. With humanity on the cusp of a biological revolution, there is a virtually endless need for more genomic information to address biology's complexity and dynamic change—and a further need to challenge conventional next-generation sequencing technologies.

Ultima Genomics正在大规模释放基因组学的力量。该公司的使命是不断推动基因组信息的规模，以实现生物学的前所未有的进步和人类健康的改善。随着人类处于生物革命的尖端，人们几乎无限地需要更多的基因组信息来解决生物学的复杂性和动态变化，并且还需要挑战传统的下一代测序技术。

Ultima's revolutionary new sequencing architecture drives down the costs of sequencing to help overcome the tradeoffs that scientists and clinicians are forced to make between the breadth, depth and frequency with which they use genomic information. The new sequencing architecture was designed to scale far beyond conventional sequencing technologies, lower the cost of genomic information and catalyze the next phase of genomics in the 21st century.

Ultima革命性的新测序架构降低了测序成本，以帮助克服科学家和临床医生被迫在使用基因组信息的广度，深度和频率之间进行权衡。新的测序体系结构旨在远远超越传统的测序技术，降低基因组信息的成本，并催化21世纪基因组学的下一阶段。

To learn more, visit www.ultimagenomics.com..

To learn more, visit www.ultimagenomics.com..